Regeneron has secured the rights to Hansoh’s late-stage GLP-1/GIP receptor agonist [HS-20094] in a significant $2 billion deal. This acquisition enables Regeneron to explore synergistic combinations with its own drugs, aiming to tackle muscle loss and potential obesity-related comorbidities like cardiovascular diseases, diabetes, and liver conditions. Boaz Hirshberg, Regeneron’s senior vice president of clinical development in internal medicine, expressed enthusiasm for the partnership’s potential in addressing a range of health issues.By in-licensing Hansoh’s GLP-1/GIP agonist, Regeneron expands its portfolio to enhance its therapeutic approach to complex conditions. The collaboration opens up possibilities for innovative treatment strategies that could benefit patients with obesity-related complications. With this strategic move, Regeneron aims to advance its research and development efforts, potentially leading to novel therapeutic solutions for a broader spectrum of health challenges. The $2 billion deal signifies a significant investment in advancing medical research and underscores Regeneron’s commitment to addressing unmet medical needs in the field of clinical development.
Read more from pmlive.com
